For: |
Fujii H, Nishimura T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Sumida Y, Mitsuyoshi H, Yokomizo C, Tanaka S, Ishikawa H, Nishioji K, Kimura H, Takami S, Nagao Y, Takeuchi T, Shima T, Sawa Y, Minami M, Yasui K, Itoh Y. Comparison of peg-interferon, ribavirin plus telaprevir |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v7/i28/2841.htm |
Number | Citing Articles |
1 |
Nabil Mohie Abdel-Hamid, Ahmed Wahid, Maiiada Hassan Nazmy, Marwa Abdel-Moniem Eisa. Synergistic Effects of Jerusalem Artichoke in Combination with Pegylated Interferon Alfa-2a and Ribavirin Against Hepatic Fibrosis in Rats. Asian Pacific Journal of Cancer Prevention 2016; 17(4): 1979 doi: 10.7314/APJCP.2016.17.4.1979
|
2 |
Satoshi Yamagiwa, Toru Ishikawa, Nobuo Waguri, Soichi Sugitani, Hiroto Wakabayashi, Shogo Ohkoshi, Takashi Tsukishiro, Toru Takahashi, Toshiaki Watanabe, Shuji Terai. Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C. World Journal of Hepatology 2017; 9(5): 252-262 doi: 10.4254/wjh.v9.i5.252
|
3 |
|
4 |
Pietro Torre, Andrea Aglitti, Mario Masarone, Marcello Persico. Viral hepatitis: Milestones, unresolved issues, and future goals. World Journal of Gastroenterology 2021; 27(28): 4603-4638 doi: 10.3748/wjg.v27.i28.4603
|
5 |
Mohamed Aboushady, Ahmed Alwassief, Mohamed Abdelrazik, Dina Ziada, Hossam Shahba, Amr Elmestikawy, Ashraf Elbahrawy. Retreatment of Egyptian Chronic Hepatitis C Patients Not Responding to Pegylated Interferon and Ribavirin Dual Therapy. Journal of Interferon & Cytokine Research 2019; 39(9): 539 doi: 10.1089/jir.2019.0041
|